BCL2 and acute myeloid leukemia: The two inhibitors sorafenib and midostaurin which are beneficial for AML patients with the FLT3 mutations, both showed significantly higher IC50 in the high-risk group (Figure 9E,F), and the hedgehog inhibitor GDC-0449 (Vismodegib) also exhibited remarkably elevated IC50 in the high-risk group (Figure 9G), while the BCL-2 inhibitor ABT-263 showed significantly lower IC50 in the high-risk group (Figure 9H).